ライフサイエンスコーパス: TAT

1 TAT is important in neuronal polarity and mechanosensati

2 TAT is inefficient, and its activity is enhanced when tu

3 TAT-4BB inhibited LPS-induced calcium changes in a major

4 TAT-CBD3 disrupted CRMP2-NMDAR interaction without chang

5 TAT-Cd degrees reduced the severity of keratitis in all

6 TAT-conjugated Pirt(N14) peptide (Pirt(N14)) is sufficie

7 TAT-FLAG GAPDH and/or Siah1-directed peptides were used

8 TAT-fused NipR1 attenuated RhoA nitration and barrier di

9 TAT-GILZ also modulated the activation of the survival-c

10 TAT-p27 was also able to provoke greater levels of autop

11 TAT-RasGAP317-326, a cell-permeable 10-amino acid-long p

12 TAT.ARC protein delivery led to a dose-dependent better

13 TAT.ARC-treated mice showed better performance in the po

14 In this study, we dimerized the HIV-1 TAT peptide and formulated a nanoparticle vector (dTAT N

15 nd, unlike human papillomavirus E6 and HIV-1 TAT proteins, LANA did not reduce TIP60 stability.

16 n of human immunodeficiency virus 1 (HIV-1) (TAT-ARC) on Fas- and tumor necrosis factor (TNF)-mediate

17 A TAT peptide containing the Gbetagamma-interacting domain

18 A TAT-FXN fusion protein bound iron in vitro, transduced i

19 1.35 A TAT cocrystal structures with bisubstrate analogs constr

20 Each eligible OR team member achieving a TAT of 60 minutes or less or an on-time FCS was awarded

21 d cell-permeable GIV-CT peptides by fusing a TAT-peptide transduction domain (TAT-PTD) to the minimal

22 TLR TIR decoy peptide modified to include a TAT sequence (Trans-Activator of Transcription gene in H

23 l data reveals the consistent formation of a TAT triad platform between the two motifs.

24 strated that intratracheal instillation of a TAT-conjugated PKCdelta inhibitory peptide (PKCdelta-TAT

25 V1 in vitro, and when covalently linked to a TAT peptide to promote uptake across the cell membrane t

26 An effective peptide, when coupled to a TAT sequence conferring cell permeability, was found to

27 By conjugating EEDs to a TAT-PTD/CPP spilt-GFP peptide complementation assay, we

28 n of NET-Thr(30) motif/phosphorylation via a TAT peptide strategy prevents cocaine-induced NET up-reg

29 ilitate the clinical development of (225) Ac TAT for the treatment of soft-tissue metastases.

30 Tubulin acetyltransferase (TAT) acetylates Lys-40 of alpha-tubulin in the microtubu

31 -tubulin Lys40 by tubulin acetyltransferase (TAT) is the only known posttranslational modification in

32 alpha-tubulin by tubulin acetyltransferase (TAT).

33 DAg-L(198-210), containing the 10-amino acid TAT peptide and HDAg-L(198-210), inhibited the interacti

34 Trans-activating transcriptional activator (TAT), a cell-penetrating peptide, is extensively used fo

35 In addition, TAT-CBD3, but not CBD3 without TAT or TAT-scramble pepti

36 surface potential on the density of adsorbed TAT.

37 egans alpha-tubulin acetyltransferase (alpha-TAT) MEC-17 allows the production of 15-p MTs in the tou

38 experiments reveal a specific role for alpha-TAT in the formation of MTs and in the production of hig

39 ddition, our results indicate that the alpha-TAT protein has functions that require acetyltransferase

40 sitive (Lgr5) and Tyrosine aminotransferase (TAT).

41 is catabolized by tyrosine aminotransferase (TAT).

42 requires attention to more than the analytic TAT, and will only occur if postanalytic processes (test

43 ychlor inhibited cortisol-stimulated Arg and TAT gene expression.

44 ts of the TAT-Sox2, TAT-Oct4, TAT-Lin28, and TAT-Nanog fusion proteins were 36kD, 40kD, 24kD, and 36k

45 n of TLRs on microglia cells by morphine and TAT in the context of S. pneumoniae infection may be a p

46 hancing ability than other polyarginines and TAT peptides.

47 ma ddPCR assay sensitivity, specificity, and TAT.

48 lays a role in the cross talk between TH and TAT and regulates contractility by influencing NE biosyn

49 FCSs improved from 31% to 64%(P < .001), and TATs of 60 minutes or less increased from 24%to 52%(P <

50 ned markedly elevated thrombin-antithrombin (TAT) complex levels (indicating uncontrolled thrombin ge

51 -peptide, proinsulin, thrombin-antithrombin (TAT) complex, and a panel of proinflammatory cytokines.

52 the concentration of thrombin-antithrombin (TAT) complexes in plasma.

53 Thrombin generation (thrombin-antithrombin [TAT] complex), endothelial dysfunction (asymmetric dimet

54 rkers of coagulation (thrombin-antithrombin [TAT]), fibrinolysis (plasmin-antiplasmin [PAP]), and com

55 the territory of the middle cerebral artery, TAT.ARC salvages brain tissue when given during occlusio

56 As TAT was added to the liposome solution the POPC surface

57 oked DA efflux in vivo to the same extent as TAT-C24WT.

58 r, CRMP2 down-regulation strongly attenuated TAT-CBD3-induced inhibition of reverse NCX.

59 The average TAT was reduced from 7 days (range, 2-14 days) to 2 days

60 However, the cross talk/link between TAT and TH in the heart is unclear.

61 sequence, but preserved CaMKIIalpha binding (TAT-C24AAA), to diminish AMPH-evoked DA efflux in vivo t

62 Chimeric proteins driven by TAT of HIV have been exploited by us to deliver viral ep

63 Specific blockage of Cx43 HC function by TAT-Gap19, a Cx43 mimetic peptide, significantly upregul

64 lux into neurons, was strongly suppressed by TAT-CBD3.

65 he N terminus of the transmembrane domain (C-TAT peptide), and studied its effects in an in vitro BBB

66 The cysteinyl moiety at position 1 of the C-TAT peptide contributes largely to the destabilizing pot

67 ll monolayer with 0.3-0.6 mumol/ml of this C-TAT peptide, for a period of 1-2 h, destabilizes brain c

68 ectrostatic interaction between the cationic TAT and anionic heparin.

69 However, the positively charged TAT peptide strongly interacts with serum components and

70 A chimeric TAT-gelonin fusion protein was genetically engineered, a

71 generate an equimolar mixture of the codons TAT, TCT, TGT and TTT at that position, encoding a mixtu

72 In comparison, TAT rigidified POPE and POPG similarly in the binary mem

73 in vitro), thrombin/antithrombin complexes (TAT; a measure of thrombin generation in vivo), tissue f

74 tructures with bisubstrate analogs constrain TAT action to the microtubule lumen and reveal Lys40 eng

75 In contrast, TAT-CBD3 augmented the CRMP2-NCX3 co-immunoprecipitation

76 activity than several other well-known CPPs (TAT, penetratin, Pep-1, and TP10).

77 ilon-caprolactone) (PEG-PCL, PECL) to get DA-TAT-PECL.

78 acid-active tumor targeting nanoplatform DA-TAT-PECL is developed to inhibit the nonspecific interac

79 amines to carboxylic acid; the resulting DA-TAT is conjugated to poly(ethylene glycol)-poly(epsilon-

80 d to the last 24 C-terminal residues of DAT (TAT-C24 DAT) and thereby contained the Ca(2+)-calmodulin

81 During glucose deprivation, TAT-p27 inhibited apoptosis, whereas down-regulation of

82 by fusing a TAT-peptide transduction domain (TAT-PTD) to the minimal modular elements of GIV that are

83 at acute myocardial dysfunction by high-dose TAT-HKII peptide administration is a consequence of impa

84 Moreover, we demonstrate that low-dose TAT-HKII treatment, which abrogates the protective effec

85 this profile resembles the greatly elevated TAT/PC activity ratios reported in patients with warfari

86 Following extinction, TAT-NET-Thr(30) when given prior to cocaine challenge si

87 Here we use dimeric fluorescence TAT as a model CPP to explore the broader consequences o

88 -SOD was conjugated to FITC-MSN forming FMSN-TAT-SOD.

89 The effectiveness of FMSN-TAT-SOD as an agent against ROS was investigated, which

90 acteristic nonendosomal distribution of FMSN-TAT-SOD.

91 Results suggested that FMSN-TAT-SOD may provide a strategy for the therapeutic deliv

92 adioimmunoconjugate labeled with (211)At for TAT.

93 e obtained the dissociation constants Kd for TAT binding to POPC and POPG liposomes and the maximum n

94 elucidate the mechanistic underpinnings for TAT activity and its preference for microtubules with sl

95 Mitochondria from TAT-HK2-perfused hearts showed no loss of bound HK2, unl

96 Functionally, TAT.ARC treatment inhibited DAXX-ASK1-JNK signaling in t

97 Further, TAT-p27 enhanced autophagy and repressed cardiomyocytes

98 GABA type A (GABAA) receptor subunit gamma2 (TAT-GABAgamma2) and muscimol, a GABAA receptor agonist.

99 neoplastic lesions by (111)In-anti-gammaH2AX-TAT (defined as >5% injected dose per gram of tissue) wa

100 2.5-fold increase in (111)In-anti-gammaH2AX-TAT accumulation in the mammary fat pads of mice aged 76

101 o investigate whether (111)In-anti-gammaH2AX-TAT detects the DDR during mammary oncogenesis in BALB-n

102 DDR imaging using (111)In-anti-gammaH2AX-TAT identified mammary tumors significantly earlier than

103 (111)In-anti-gammaH2AX-TAT or a control probe was administered intravenously to

104 ator phenotype, with markedly elevated TCT-->TAT and TCG-->TTG mutations and overall mutation frequen

105 In the perfused rat heart, TAT-HK2 should be used with caution and careful attentio

106 nd two cell-penetrating peptides (CPPs), HIV TAT and penetratin.

107 netrating peptide (CPP) conjugate of the HIV TAT protein that is fused to an aminoterminal sequence o

108 rans-Activator of Transcription gene in HIV; TAT-4BB) affected LPS-induced intracellular calcium flux

109 However, TAT-HK2 also decreased the phosphocreatine:ATP ratio tha

110 In comparison I, TATs for 61,157 urine cultures were extracted for two pe

111 MALDI-TOF MS significantly improved TAT for organism ID.

112 son II results, MALDI significantly improved TAT to organism ID compared to CONV (21.3 to 18 h).

113 In summary, TLA significantly improved TAT to organism ID, AST report, and preliminary negative

114 ettings resulting in the largest decrease in TAT and mechanical interventricular dyssynchrony, wherea

115 - SD; p = 0.005; T2-weighted MRI) smaller in TAT.ARC-treated mice (1 mug intraventricularly during MC

116 and tolyfluanid attenuated cortisol-induced TAT expression.

117 Szyk et al. now provide insight into TAT's mechanism of action and its unique time-stamping a

118 d in rat hearts perfused with 2.5 micromol/L TAT-HK2 before ischemia or at the onset of reperfusion.

119 erved, albeit less pronounced, at 200 nmol/L TAT-HK2 and was prevented by coperfusion with the NO-don

120 ither by the previously described PDZ ligand TAT-GESV or by the ExF motif-bearing region of NOS1AP, e

121 the confined intraluminal location of Lys40, TAT efficiently scans the microtubule bidirectionally an

122 Before FIP implementation, the mean TAT varied between 77 and 83 minutes, with only 18%to 26

123 s postinfection in mice treated with 1 mg/mL TAT-Cd degrees , suggesting that inhibiting replication

124 Moreover, TAT-Kalpha2 peptide protected the mice, that were challe

125 In the presence of an intact GEF motif, TAT-GIV-CT peptides enhanced diverse processes in which

126 cells, we also found that TAT-C24WT, but not TAT-C24Scr, decreased AMPH-evoked 1-methyl-4-phenylpyrid

127 systemic administration of TAT-C24WT but not TAT-C24Scr.

128 istration of TAT-NET-Thr(30) peptide but not TAT-NET-T30A (mutant peptide) completely blocked cocaine

129 digm, mice receiving TAT-NET-Thr(30) but not TAT-NET-T30A on postconditioning test day exhibited sign

130 molecular weights of the TAT-Sox2, TAT-Oct4, TAT-Lin28, and TAT-Nanog fusion proteins were 36kD, 40kD

131 The ability of TAT-C24WT but not a scrambled peptide (TAT-C24Scr) to bl

132 s further clarify the mechanism of action of TAT-CBD3 and identify a novel regulatory checkpoint for

133 sensitizing and antimetastatic activities of TAT-RasGAP317-326.

134 26 sequence for the anticancer activities of TAT-RasGAP317-326.

135 portantly, intraperitoneal administration of TAT-C1aB in mice following transient middle cerebral art

136 enuated following systemic administration of TAT-C24WT but not TAT-C24Scr.

137 served, when compared with administration of TAT-gelonin alone.

138 Therapeutic administration of TAT-GILZ induced inflammation resolution, decreased cyto

139 In vivo administration of TAT-NET-Thr(30) peptide but not TAT-NET-T30A (mutant pep

140 Furthermore, topical application of TAT-GIV-CT peptides enhanced the complex, multireceptor-

141 ce-selective method, to study the binding of TAT to anionic 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho

142 t by simply changing the relative content of TAT/CGC triplets in the switches, we can rationally tune

143 ignificantly augmented (58-fold) delivery of TAT-gelonin to the tumor target was observed, when compa

144 Finally, intra-striatal delivery of TAT-GluN1C1 did not affect acute responses to cocaine bu

145 Delayed delivery of TAT.ARC may present a promising target for stroke therap

146 dissection of TAT activity and the design of TAT inhibitors with therapeutic potential in neuronal re

147 l platform for the mechanistic dissection of TAT activity and the design of TAT inhibitors with thera

148 , cardiac NE, beta-AR, and downregulation of TAT and plasma levels of NE.

149 et al argue that the deleterious effects of TAT-HKII administration on cardiac function are likely b

150 ngs challenge the notion that the effects of TAT-HKII are attributable to impaired vascular function

151 the efficacy of TAT-CD degrees was assessed in a postinfection treatment

152 After 4-h incubation of TAT-NS on BT549 breast cancer cells, photothermolysis wa

153 Injection of TAT-FXN protein into mice with a conditional loss of FXN

154 d to inhibit the nonspecific interactions of TAT in the bloodstream.

155 lipopolysaccharide and bacteremia but not of TAT and PAP.

156 domain that modulates the oligomerization of TAT in solution and is essential for activity.

157 s and thus to accelerate the optimization of TAT.

158 TH, whereas knockdown and overexpression of TAT demonstrated that TAT inhibited TH.

159 r delivery and efficient photothermolysis of TAT-NS, promising agents in cancer therapy.

160 se phenotype, and present the possibility of TAT-FXN as a protein replacement therapy.

161 n-induced apoptosis, even in the presence of TAT-p27.

162 33a overexpression prevented upregulation of TAT and suppression of TH in the heart after streptozoto

163 een 77 and 83 minutes, with only 18%to 26%of TATs being 60 minutes or less; on-time FCSs averaged 29%

164 Effectively communicating the importance of TATs and on-time FCSs and publishing individual results

165 and POPG liposomes and the maximum number of TATs that can bind to a given liposome surface.

166 Inclusion of (Arg)9 or TAT(57-57) CPPs further modified the translation readout

167 alphaB-crystallins produced by fusing gC or TAT were over-expressed in E. coli.

168 Parnate, an enzymatic inhibitor of LSD1, or TAT-SNAG, a cell-permeable peptide corresponding to the

169 and TseL, despite lacking a classical Sec or TAT secretion signal, were able to reach the periplasm w

170 ition, TAT-CBD3, but not CBD3 without TAT or TAT-scramble peptide, inhibited increases in cytosolic C

171 Outcomeswere TAT, whichwas defined as "wheels out" to "wheels in," an

172 TLA further improved overall TAT to ID (18 to 16.5 h) and AST (42.3 to 40.7 h) result

173 P110-TAT treatment also reduced the extent of neurite shorten

174 P110-TAT treatment of fibroblasts from patients with HD and p

175 excessive mitochondrial fission with a P110-TAT-like inhibitor may prevent or slow the progression o

176 Furthermore, P110-TAT treatment suppressed mtHtt-induced association of p5

177 We developed a selective inhibitor (P110-TAT) of the mitochondrial fission protein dynamin-relate

178 We found that P110-TAT inhibited mtHtt-induced excessive mitochondrial frag

179 r, treatment of HD transgenic mice with P110-TAT reduced mitochondrial dysfunction, motor deficits, n

180 nd Doxil(R)), modified with cell-penetrating TAT peptide (TATp) moieties and cancer-specific mAb 2C5

181 pplication of a NF-kappaB inhibitory peptide TAT-NBD or GAP43(S41A) (dominant-negative GAP43) or knoc

182 dification with the cell penetrating peptide TAT facilitates brain-specific delivery that is restrict

183 oparticles with the cell-penetrating peptide TAT increases their biophysical association with cell su

184 abeled dimer of the cell-penetrating peptide TAT, dfTAT, penetrates live cells by escaping from endos

185 ide linker (pp), a cell penetrating peptide (TAT), and a model drug (doxorubicin).

186 1 association with a cell-permeable peptide (TAT-GluN1C1) left individual D1R and NMDAR-dependent sig

187 The resulting peptide (TAT-C1aB) suppressed enhanced whole-cell K(+) currents p

188 ty of TAT-C24WT but not a scrambled peptide (TAT-C24Scr) to block the CaMKIIalpha-DAT interaction was

189 th trans-activator of transcription peptide (TAT)-GILZ, a cell-permeable GILZ fusion protein, shorten

190 Furthermore, a peptide, TAT-HDAg-L(198-210), containing the 10-amino acid TAT pe

191 aptic currents, whereas the control peptide, TAT-myc, had no effect.

192 s) conjugated to a cell-penetrating peptide, TAT, was used to increase intracellular delivery of pacl

193 We saved 13 minutes per TAT, for an estimated savings of $177 000.We estimate an

194 d190, we generated a cell membrane-permeable TAT-Runx1.d190 fusion protein.

195 ugated PKCdelta inhibitory peptide (PKCdelta-TAT) is lung protective in a rat model of sepsis-induced

196 epatocellular and endothelial damage, plasma TAT concentration, and hepatic platelet accumulation wer

197 t affect APAP-induced liver injury or plasma TAT levels.

198 Prolonged TATs and late FCSs occur frequently at academic medical

199 expression in the presence of HIV-1 protein TAT and S. pneumoniae with a significant increase in pro

200 at ectopic delivery of a p27 fusion protein (TAT-p27) was sufficient to induce autophagy in neonatal

201 ransduction domain of the HIV-1 Tat protein (TAT-C24WT).

202 ciency virus 1 (HIV) transactivator protein (TAT) to mesoporous silica nanoparticle is shown to be an

203 cell-penetrating motif of the HIV-1 protein, TAT-CBD3, but not CBD3 without TAT, attenuated N-methyl-

204 The purified TAT-SOD was conjugated to FITC-MSN forming FMSN-TAT-SOD.

205 Median (range) TAT for plasma ddPCR was 3 (1-7) days.

206 Tissue genotyping median (range) TAT was 12 (1-54) days for patients with newly diagnosed

207 free tubulin and its modest catalytic rate, TAT can function as a slow clock for microtubule lifetim

208 In the cocaine CPP paradigm, mice receiving TAT-NET-Thr(30) but not TAT-NET-T30A on postconditioning

209 ath domain of the p75 neurotrophin receptor (TAT-Pep5) and in mice lacking the extracellular neurotro

210 the intravenous injection of the recombinant TAT-Cre protein alters the amplitude of the preovulatory

211 ide (Abeta1-6A2V), linked to the HIV-related TAT protein, which is widely used for brain delivery and

212 significant decreases in microbiology report TATs.

213 he thylakoid membrane and lumen by the SEC1, TAT, or SRP/ALB3 translocases.

214 adhesion molecule-1, E-selectin, P-selectin, TAT (thrombin/antithrombin complex), tumor necrosis fact

215 l d 1 was fused to a translocation sequence (TAT) and to part of the human invariant chain, generatin

216 The molecular weights of the TAT-Sox2, TAT-Oct4, TAT-Lin28, and TAT-Nanog fusion proteins were

217 rpart on beta-arrestin-2 or using a specific TAT-P1 peptide to block the interaction between beta-arr

218 pression in CATH.a neuronal cells suppressed TAT with concomitant upregulation of TH, whereas knockdo

219 The His-tagged TAT-SOD fusion protein was expressed in E. coli using IP

220 tor to produce a genetic in-frame His-tagged TAT-SOD fusion protein.

221 ontractility of diabetic hearts by targeting TAT, regulating NE biosynthesis, and consequently, beta-

222 porter assay confirmed that miR-133a targets TAT.

223 CRMP2 interacts with NCX and NMDAR and that TAT-CBD3 protects against glutamate-induced Ca(2+) dysre

224 at rest and after metabolic stress, and that TAT-p27 inhibits apoptosis by promoting autophagy in glu

225 ingle-molecule measurements demonstrate that TAT catalytic activity, not constrained luminal diffusio

226 and overexpression of TAT demonstrated that TAT inhibited TH.

227 In heterologous cells, we also found that TAT-C24WT, but not TAT-C24Scr, decreased AMPH-evoked 1-m

228 Mechanistically, we found that TAT-Kalpha2 peptide destabilized the viral membranes, de

229 We found that TAT-STEP, a peptide that renders STEP enzymatically inac

230 rane at ambient temperature, indicating that TAT does not cause dynamic heterogeneity but interacts w

231 ing with an anti-NCX3 antibody revealed that TAT-CBD3 induced NCX3 internalization, suggesting that b

232 says with diverse tubulin polymers show that TAT is stimulated by microtubule interprotofilament cont

233 We show that TAT-peptide-functionalized gold nanostars (NS) enter cel

234 This study shows that TAT-Cd degrees is an effective antiviral against HSV-1 s

235 These results suggest that TAT-Kalpha2 peptide is a potential antiviral agent for c

236 The TAT for nevi decreased from 2 days to 1 day, for melanom

237 the nAPCsr was lower in treated men and the TAT level was lower in untreated individuals.

238 4 (BMP4), EGF, or PDGF was unaffected by the TAT-SNX9 peptide.

239 ce of amino acids in the protein, called the TAT peptide, enables the TAT protein to penetrate cell m

240 maleic anhydride (DA) is used to convert the TAT's amines to carboxylic acid; the resulting DA-TAT is

241 protein, called the TAT peptide, enables the TAT protein to penetrate cell membranes.

242 six polyethylene glycol (PEG) units from the TAT-PTD-cargo significantly enhanced cytoplasmic deliver

243 eshielding and exposure of the TAT; (iv) the TAT-mediated cell internalization; (v) the TAT-induced e

244 ctures formed in the absence of ligands, the TAT triad interface occludes ligand binding at the 3' qu

245 ing activity, warning against the use of the TAT carrier in the design of AD therapeutics.

246 chanisms of binding and translocation of the TAT peptide into the cell, investigators have used phosp

247 Acute systemic administration of the TAT-4BB reversed M3G-induced tactile allodynia in a dose

248 Efficient cellular uptake of the TAT-conjugated PLGA NPs was observed; however, it did no

249 The molecular weights of the TAT-Sox2, TAT-Oct4, TAT-Lin28, and TAT-Nanog fusion prot

250 mediated PEG deshielding and exposure of the TAT; (iv) the TAT-mediated cell internalization; (v) the

251 efficacy studies also revealed that only the TAT-gelonin/T84.66-Hep complex yielded a significant inh

252 -amino acid peptide from CRMP2, fused to the TAT cell-penetrating motif of the HIV-1 protein, TAT-CBD

253 with Abeta1-6A2VTAT(D) was likely due to the TAT intrinsic attitude to increase Abeta production, avi

254 ion of the Poisson-Boltzmann equation to the TAT liposome SHG data, was shown to be in good agreement

255 tor insertion in the cell membrane using the TAT-GABAgamma2 peptide in the dorsal mPFC, but not the v

256 nting the nuclear import of pSMAD3 using the TAT-SNX9 peptide inhibited profibrotic TGF-beta activity

257 e TAT-mediated cell internalization; (v) the TAT-induced endosomal escape; (vi) the inhibition of P-g

258 oprotein mediated drug efflux; and (vii) the TAT-medicated nuclear translocation.

259 Furthermore, while the TAT-SNX9 peptide prevented TGF-beta's profibrotic activi

260 ment with the Kalpha2 peptide fused with the TAT peptide significantly inhibited IAV replication and

261 225) Ac chelation in targeted alpha therapy (TAT).

262 Targeted alpha-therapy (TAT) appears to be an ideal therapeutic technique for el

263 Thus, TAT-GIV peptides provide a novel and versatile tool to m

264 Total activation time (TAT) was calculated from >100 contact mapping electrodes

265 ecimen containers, and long turnaround time (TAT) hindered access to quality laboratory services.

266 phylococcus QuickFISH has a turnaround time (TAT) of <30 min and a hands-on time (HOT) of <5 min.

267 However, improving the turnaround time (TAT) of a test requires attention to more than the analy

268 e specimen can increase the turnaround time (TAT) significantly.

269 Test turnaround time (TAT) was measured in business days from blood sampling u

270 Operating room (OR) turnaround times (TATs) and on-time first-case starts (FCSs) are commonly

271 technologies, we compared turnaround times (TATs) for positive and negative urine cultures before an

272 ulness of EVD with DD, and turnaround times (TATs).

273 ulness of EVD with DD, and turnaround times (TATs).

274 mparison I results, median pre- and post-TLA TATs to organism IDs (18.5 to 16.9 h), AST results (41.8

275 revented NCX3 internalization in response to TAT-CBD3 exposure.

276 ices and a C-terminal beta-hairpin unique to TAT.

277 When mixing together, TAT-gelonin and T84.66-Hep could associate tightly and a

278 ly significant losses of median (IQR) total (TAT, 2.9% (-9.8, 0.7), p = 0.03) and subcutaneous (SAT,

279 A transactivator of transcription (TAT) peptide strategy was utilized to test the involveme

280 we used the transactivator of transcription (TAT) protein transduction domain to deliver human FXN pr

281 e effect of transactivator of transcription (TAT) protein transduction of the apoptosis repressor wit

282 e expressed transactivator of transcription (TAT)-fused proteins, Sox2, Oct4, Lin28, and Nanog in Sf9

283 ing peptide transactivator of transcription (TAT).

284 vels, demonstrated here using a transducible TAT-UCH-L1 strategy.

285 The transacting activator of transduction (TAT) protein plays a key role in the progression of AIDS

286 The wild-type TAT construct is a monomer in solution.

287 n domain of the human immunodeficiency virus TAT protein (Tat), an Angiopep peptide (Ang-2), and the

288 n domain of the human immunodeficiency virus TAT protein, were tested in in vitro and in vivo experim

289 ly, survival of mice was even preserved when TAT-ARC therapy was initiated in a delayed manner after

290 NF-kappaB inhibitor-treated groups, whereas TAT levels were elevated in all three groups with a peak

291 r performance in the pole test compared with TAT.beta-Gal-treated controls.

292 Blocking neutrophil degranulation with TAT-SNAP23 fusion protein significantly reduced the chem

293 study, we fused a human Cu,Zn-SOD gene with TAT in a bacterial expression vector to produce a geneti

294 These changes were linked with TAT-Gap19-induced suppression of ATP signaling and activ

295 PH-evoked DA efflux in mice preinjected with TAT-C24WT.

296 In vitro treatment of synaptosomes with TAT-NET-Thr(30) (wild-type peptide) completely blocked c

297 Murine splenocytes treated with TAT-Runx1.d190 showed an increase in the transcription o

298 Treatment with TAT-ARC protein completely abrogated otherwise lethal li

299 In addition, TAT-CBD3, but not CBD3 without TAT or TAT-scramble peptide, inhibited increases in cyto

300 IV-1 protein, TAT-CBD3, but not CBD3 without TAT, attenuated N-methyl-d-aspartate receptor (NMDAR) ac